Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 45, pages 1088–1094 (2010)Cite this article

Abstract

We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusion in two equally divided doses. The area under the concentration–time curve during oral administration (AUCPO) was significantly higher than the AUC during intravenous infusion (AUCIV) (median 7508 vs 6705 ng/ml × h, P=0.050). The median bioavailability of Neoral, defined as (AUCPO/DOSEPO) divided by (AUCIV/DOSEIV), was 0.685 (range, 0.45–1.04). Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole. Although the conversion from intravenous to oral administration of CsA at a ratio of 1:2 seemed to be appropriate in most patients, a lower conversion ratio may be better in patients taking oral voriconazole. To obtain a similar AUC, the target trough concentrations during twice-daily oral administration should be halved compared with the target concentration during continuous infusion.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF . A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759–764.

    Article  CAS  PubMed  Google Scholar 

  2. Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006; 81: 838–844.

    Article  CAS  PubMed  Google Scholar 

  3. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008; 83: 226–232.

    Article  CAS  PubMed  Google Scholar 

  4. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K . The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935–2939.

    CAS  PubMed  Google Scholar 

  5. Parquet N, Reigneau O, Humbert H, Guignard M, Ribaud P, Socié G et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2000; 25: 965–968.

    Article  CAS  PubMed  Google Scholar 

  6. McGuire TR, Honaker M, Lynch JC, Tarantolo SR, Bishop MR, Ketcham MA et al. Renal dysfunction associated with cyclosporine (CSA) prophylaxis in HLA matched sibling peripheral blood stem cell transplantation (AlloBSCT): conversion from intravenous CSA to a new oral formulation (Neoral). Blood 1999; 94 (Suppl 1): 334A abstr 1492.

    Google Scholar 

  7. Okuda S, Terasako K, Oshima K, Sato M, Nakasone H, Kako S et al. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Am J Hematol 2009; 84: 167–169.

    Article  CAS  PubMed  Google Scholar 

  8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  9. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83: 472–476.

    Article  CAS  PubMed  Google Scholar 

  10. Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437–444.

    Article  CAS  PubMed  Google Scholar 

  11. Wolf BA, Daft MC, Koenig JW, Flye MW, Turk JW, Scott MG . Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H- or 125I-labeled ligand compared. Clin Chem 1989; 35: 120–124.

    CAS  PubMed  Google Scholar 

  12. Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Transplant Proc 2005; 37: 1725–1727.

    Article  CAS  PubMed  Google Scholar 

  13. Ku YM, Min DI, Flanigan M . Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 1998; 38: 959–965.

    Article  CAS  PubMed  Google Scholar 

  14. Leather HL . Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 2004; 33: 137–152.

    Article  CAS  PubMed  Google Scholar 

  15. Dresser GK, Spence JD, Bailey DG . Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57.

    Article  CAS  PubMed  Google Scholar 

  16. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ . Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014–1018.

    Article  CAS  PubMed  Google Scholar 

  17. Lopez-Gil JA . Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993; 27: 427–430.

    Article  CAS  PubMed  Google Scholar 

  18. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR . Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268–1272.

    Article  CAS  PubMed  Google Scholar 

  19. Mihara A, Mori T, Aisa Y, Yamazaki R, Iketani O, Tanigawara Y et al. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol 2008; 64: 89–91.

    Article  CAS  PubMed  Google Scholar 

  20. Kramer MR, Merin G, Rudis E, Bar I, Nesher T, Bublil M et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc 1997; 29: 2657–2659.

    Article  CAS  PubMed  Google Scholar 

  21. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP . Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003; 35: 2873–2877.

    Article  CAS  PubMed  Google Scholar 

  22. Leather H, Boyette RM, Tian L, Wingard JR . Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 325–334.

    Article  CAS  PubMed  Google Scholar 

  23. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S . Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009; 44: 371–374.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported in part by grants from the Ministry of Health, Labor and Welfare of Japan.

Author information

Author notes

  1. S Kimura, K Oshima and S Okuda: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    S Kimura, K Oshima, S Okuda, K Sato, M Sato, K Terasako, H Nakasone, S Kako, R Yamazaki, Y Tanaka, A Tanihara, T Higuchi, J Nishida & Y Kanda

Authors
  1. S Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Okuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Terasako
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Nakasone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Kako
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Tanihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. T Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Kanda.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimura, S., Oshima, K., Okuda, S. et al. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 45, 1088–1094 (2010). https://doi.org/10.1038/bmt.2009.316

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.316

Keywords

This article is cited by

Search

Advanced search

Quick links